Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT07787156
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Family History of Pancreas Cancer
  • Genetic Testing
  • Multi-cancer Early Detection
  • Pancreatic Ductal Adenocarcinoma (PDAC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Telephone education session — BEHAVIORAL
    Participants will receive a telephone call from a trained navigator at PanCAN to provide \~20mins of information about genetic testing and MCED testing.
  • Online educational materials — BEHAVIORAL
    Participants will receive links to test information provided by the testing company.

Study Details

This study will test a remote approach to help people who may be at higher risk for pancreatic cancer learn about and decide whether to get genetic testing and a blood test that looks for signs of several cancers (MCED testing). The study is focused on Black, Latino/a, and Medicaid-enrolled individuals who may have had less access to cancer genetics and early detection services. About 80 participants, who reside in Massachusetts, will be assigned by chance to receive either online education alone or online education plus a phone call with a trained educator from the Pancreatic Cancer Action Network (PanCAN). After the education, participants can choose whether or not to have genetic testing and/or MCED testing. The main goal is to learn whether this approach is practical to carry out, acceptable to participants, and delivered as planned. Participants will complete 3 surveys during study participation.

Key Dates

First listed
Aug 26, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Sep 30, 2028
Completion
Mar 31, 2029

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Telephone education session plus online educational materials
    Participants will receive information about genetic testing and MCED testing through a telephone education session, in addition to receiving emailed links to online educational materials from the testing company.
  • Active Comparator: Online educational materials only
    Participants will be emailed links to online educational materials from the testing company

Primary Outcome Measure

Feasibility of completion of genetic testing and MCED testing [ Time Frame: Within 6 months of randomization ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InstituteBostonMassachusetts02215
Ishmarie Colon-Rivera, MPH
[email protected]
857-215-1892
Jenna Beckwith, MPH
[email protected]
857-215-1892
Nicolette J Rodriguez, MD, MPH (PRINCIPAL_INVESTIGATOR)
Sapna Syngal, MD, MPH (SUB_INVESTIGATOR)
Elizabeth O'Donnell, MD (SUB_INVESTIGATOR)
Catherine Marinac, PhD (SUB_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Dana-Farber Cancer Institute· Boston, MA

Related Studies